Drug Profile
SARS-CoV-2 vaccine - EpiVax/University of Georgia
Alternative Names: COVID-19 vaccineLatest Information Update: 20 Jan 2022
At a glance
- Originator EpiVax; University of Georgia
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research COVID 2019 infections
Most Recent Events
Development Overview
Introduction
A vaccine is being developed by EpiVax and University of Georgia for the prevention of prevention of COVID-19 infections caused due to coronavirus (SARS-CoV-2). EpiVax is applying its vaccine re-engineering approach to identify the key regions of viral sequences that should be included in vaccines to keep individuals safe from infection, while excluding other sequences that make the vaccine less effective or safe. Early research is ongoing in the US.
Company Agreements
In March 2020, EpiVax entered onto a collaboration agreement with University of Georgia to develop a novel coronavirus SARS-CoV-2 (COVID-19) vaccine. Financial terms of the agreement were not disclosed. [1]
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Biomarker
| Drug Name | Biomarker Name | Biomarker Function |
|---|---|---|
| SARS-CoV-2 vaccine - EpiVax/University of Georgia | ACE2 | Outcome Measure |
| Alkaline phosphatase (ALPL) | Eligibility Criteria | |
| AMH | Detailed Description, Outcome Measure | |
| Apolipoprotein H antibodies | Eligibility Criteria | |
| ATP citrate lyase | Outcome Measure | |
| B-cell lymphoma 2 (Bcl-2) | Arm Group Description | |
| B-lymphocyte antigen CD19 | Arm Group Description, Arm Group Label, Detailed Description | |
| B-lymphocyte antigen CD20 | Arm Group Description, Brief Title, Detailed Description, Official Title | |
| Bilirubin | Eligibility Criteria | |
| C-C motif chemokine 4 (CCL4 | Outcome Measure | |
| C-C motif chemokine 5 (CCL5 | Outcome Measure | |
| C-C motif chemokine ligand 20 | Outcome Measure | |
| C-C motif chemokine ligand 8 | Outcome Measure | |
| C-reactive protein (CRP) | Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| C-X-C motif chemokine ligand 11 | Outcome Measure | |
| C-X-C motif chemokine ligand 5 | Outcome Measure | |
| C1QL1 | Outcome Measure | |
| Calprotectin | Detailed Description | |
| Cardiac Troponin I | Eligibility Criteria, Outcome Measure | |
| CBLIF | Outcome Measure | |
| CD22 | Arm Group Description | |
| CD3 gamma chain (CD3G) | Detailed Description, Outcome Measure | |
| CD38 | Outcome Measure | |
| CD40 ligand (CD40L) | Outcome Measure | |
| CD40/TNFRSF5 | Outcome Measure | |
| CD45 (leukocyte common antigen) | Detailed Description | |
| CD56 | Detailed Description | |
| CGA | Eligibility Criteria | |
| Chemokine IFN-γ-inducible protein 10 (IP-10/CXCL10) | Outcome Measure | |
| chorionic gonadotropin beta subunit 5 | Eligibility Criteria | |
| corticotropin releasing hormone | Outcome Measure | |
| CXCL1 | Outcome Measure | |
| CXCL9 | Outcome Measure | |
| Cytokeratin 20 | Arm Group Description, Detailed Description | |
| cytotoxic T-lymphocyte-associated protein 4 | Eligibility Criteria | |
| D-dimer | Eligibility Criteria | |
| D-Urobilinogen | Eligibility Criteria | |
| Eotaxin (CCL11) | Outcome Measure | |
| Estradiol-17beta 3-sulfate | Outcome Measure | |
| Fc fragment of IgG, low affinity IIIb, receptor (CD16b) | Detailed Description | |
| Fc gamma RIIIa | Detailed Description | |
| Ferritin | Eligibility Criteria, Outcome Measure | |
| Ferrocytochrome | Eligibility Criteria | |
| Fibrinogen | Eligibility Criteria | |
| FSH | Eligibility Criteria | |
| fuzzy planar cell polarity protein | Outcome Measure | |
| Glycerophosphocholine | Eligibility Criteria | |
| GNPTAB | Eligibility Criteria | |
| GTP binding protein 1 | Outcome Measure | |
| Gut Microbiome | Brief Title, Official Title | |
| GZMB | Outcome Measure | |
| heat shock 27kDa protein 3 | Outcome Measure | |
| HLA-DR | Outcome Measure | |
| hypertrichosis 2 (generalized, congenital) | Eligibility Criteria | |
| immunoglobulin heavy constant epsilon | Outcome Measure | |
| immunoglobulin heavy constant gamma 3 (G3m marker) | Outcome Measure | |
| Insulin | Brief Summary, Outcome Measure | |
| Interferon alpha (IFN-alpha) | Outcome Measure | |
| Interferon Gamma (IFNg) | Brief Summary, Detailed Description, Outcome Measure | |
| Interleukin 1 Beta (IL-1β) | Outcome Measure | |
| interleukin 33 | Outcome Measure | |
| interleukin 37 | Outcome Measure | |
| interleukin 6 receptor | Eligibility Criteria | |
| Interleukin-10 (IL-10) | Outcome Measure | |
| Interleukin-12A (IL-12p35) | Eligibility Criteria | |
| Interleukin-12B (IL-12p40) | Eligibility Criteria | |
| Interleukin-13 (IL-13) | Outcome Measure | |
| Interleukin-17 (IL-17) | Eligibility Criteria, Outcome Measure | |
| Interleukin-18 (IL-18) | Detailed Description, Outcome Measure | |
| Interleukin-2 (IL-2) | Detailed Description, Outcome Measure | |
| Interleukin-23 (IL-23) | Outcome Measure | |
| Interleukin-4 (IL-4) | Detailed Description, Outcome Measure | |
| Interleukin-5 (IL-5) | Outcome Measure | |
| Interleukin-6 (IL-6) | Eligibility Criteria, Outcome Measure | |
| Interleukin-8 (IL-8) | Outcome Measure | |
| KRT88P | Eligibility Criteria | |
| L-Lactic acid | Eligibility Criteria | |
| L-selectin | Outcome Measure | |
| Lactate dehydrogenase (LDH) | Detailed Description | |
| lunapark, ER junction formation factor | Outcome Measure | |
| MAFB | Outcome Measure | |
| major histocompatibility complex, class II, DR beta 1 | Detailed Description, Outcome Measure | |
| MIP-1 alpha | Outcome Measure | |
| Monocyte chemoattractant protein-1 (MCP-1/CCL2) | Outcome Measure | |
| Monocyte differentiation antigen CD14 | Detailed Description | |
| mutated in colorectal cancers | Brief Summary | |
| Nuclear protein Ki67 | Outcome Measure | |
| PCNA | Arm Group Label | |
| PD-1/CD279 | Eligibility Criteria, Outcome Measure | |
| PD-L1/CD274 | Brief Title, Eligibility Criteria, Official Title, Outcome Measure | |
| perforin 1 (pore forming protein) | Outcome Measure | |
| Phosphonoacetate | Outcome Measure | |
| Picolinic acid | Outcome Measure | |
| prion protein (testis specific) | Outcome Measure | |
| Progesterone | Brief Summary, Detailed Description, Outcome Measure | |
| Protein S | Detailed Description, Outcome Measure | |
| protein tyrosine phosphatase, non-receptor type 6 | Eligibility Criteria | |
| Protoporphyrin IX | Eligibility Criteria | |
| pyrroline-5-carboxylate reductase 1 | Outcome Measure | |
| RBP4 | Outcome Measure | |
| Rheumatoid factor | Outcome Measure | |
| secretin | Detailed Description, Outcome Measure | |
| serine peptidase inhibitor, Kunitz type 1 | Outcome Measure | |
| serine racemase | Outcome Measure | |
| seryl-tRNA synthetase | Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| small nucleolar RNA, H/ACA box 73A | Detailed Description | |
| Soluble transferrin receptor | Outcome Measure | |
| suppression of tumorigenicity 14 (colon carcinoma) | Outcome Measure | |
| T-box 1 | Eligibility Criteria | |
| T-Cell differentiation antigen CD8 | Detailed Description, Outcome Measure | |
| T-cell receptor CD3-epsilon (CD3e) | Detailed Description, Outcome Measure | |
| T-cell receptor T3 delta chain (CD3d) | Detailed Description, Outcome Measure | |
| T-cell surface antigen CD4 | Detailed Description, Eligibility Criteria, Outcome Measure | |
| TF | Outcome Measure | |
| Thromboxane | Outcome Measure | |
| Toll-Like Receptor 4 (TLR4) | Outcome Measure | |
| Tumor necrosis factor alpha (TNF-alpha) | Eligibility Criteria, Outcome Measure | |
| tumor necrosis factor receptor superfamily member 9 | Outcome Measure | |
| Vitamin A | Outcome Measure | |
| vitronectin | Arm Group Description, Arm Group Label, Detailed Description, Official Title, Outcome Measure | |
| Y Chromosome | Eligibility Criteria | |
| zinc finger protein 415 | Arm Group Description |
For more detail, check out BiomarkerBase: the leading source of information about biomarkers used in drug development and diagnostic tests, tracking a comprehensive list of biomarker uses worldwide by over 800 companies
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Prevention | Research | USA | unspecified / unspecified | EpiVax, University of Georgia | 04 Mar 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| University of Georgia | Originator | USA |
| EpiVax | Originator | USA |
| University of Georgia | Owner | USA |
| EpiVax | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 17 Jan 2022 | Biomarker Update | Biomarkers information updated Updated 20 Jan 2022 |
| 04 Mar 2020 | Licensing Status | EpiVax and University of Georgia collaborate to develop COVID-19 vaccine [1] Updated 20 Mar 2020 |
| 04 Mar 2020 | Phase Change | Early research in COVID-2019 infections (Prevention) in USA (unspecified route) [1] Updated 20 Mar 2020 |
References
-
EpiVax Accelerates COVID-19 Vaccine Development with UGA's Center for Vaccines and Immunology.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG